Your session is about to expire
← Back to Search
Cephalosporin
Cefiderocol for Pharmacokinetics
Phase 1
Waitlist Available
Research Sponsored by Hartford Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 to 12 hours
Awards & highlights
Summary
This trial is designed to assess how a new broad-spectrum antibiotic, Cefiderocol, is affected by continuous renal replacement therapies (CRRT), which are used to provide renal support for critically ill patients with acute kidney injury (AKI).
Who is the study for?
This trial is for adults on continuous renal replacement therapy (CRRT) due to acute kidney injury. It's not for those with severe liver injury, pregnant or breastfeeding women, people allergic to β-lactam antibiotics, those with very low hemoglobin levels, or anyone with a life-threatening illness that could interfere with the study.Check my eligibility
What is being tested?
The study tests how Cefiderocol, a new broad-spectrum antibiotic, behaves in the body of critically ill patients who are receiving CRRT. The goal is to understand if and how dosing should be adjusted in these patients.See study design
What are the potential side effects?
Potential side effects of Cefiderocol may include allergic reactions similar to other β-lactam antibiotics such as skin rashes or more serious hypersensitivity responses.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 to 12 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 to 12 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Cefiderocol clearance
Cefiderocol concentration
Cefiderocol maximum concentration
Side effects data
From 2019 Phase 3 trial • 300 Patients • NCT0303238015%
Urinary tract infection
11%
Hypokalaemia
9%
Diarrhoea
8%
Anaemia
6%
Pleural effusion
6%
Aspartate aminotransferase increased
5%
Cardiac arrest
5%
Atrial fibrillation
5%
Constipation
5%
Alanine aminotransferase increased
5%
Hypomagnesaemia
4%
Acute respiratory failure
4%
Pneumonia
4%
Hypoglycaemia
3%
Nausea
3%
Decubitus ulcer
3%
Hyperkalaemia
3%
Pyrexia
3%
Clostridium difficile infection
3%
Septic shock
3%
Multiple organ dysfunction syndrome
3%
Hypocalcaemia
3%
Hydrothorax
3%
Urinary tract infection fungal
3%
Gamma-glutamyltransferase increased
3%
Transaminases increased
3%
Hypoalbuminaemia
3%
Hyponatraemia
3%
Hyperglycaemia
3%
Hypertension
3%
Thrombocytosis
3%
Delirium
3%
Insomnia
2%
Amylase increased
2%
Cardio-respiratory arrest
2%
Hypoproteinaemia
2%
Hepatic enzyme increased
2%
Pneumonia aspiration
2%
Bradycardia
2%
Anxiety
2%
Phlebitis
2%
Sepsis
2%
Pulmonary artery thrombosis
2%
Post procedural haemorrhage
2%
Hyperuricaemia
2%
Iron deficiency anaemia
2%
Headache
1%
Bronchitis
1%
Bacteraemia
1%
Vomiting
1%
Autonomic nervous system imbalance
1%
Cerebral ischaemia
1%
Metabolic encephalopathy
1%
Cardiac failure
1%
Cardiovascular insufficiency
1%
Sudden death
1%
Thrombocytopenia
1%
Abdominal wall haematoma
1%
Spinal cord infection
1%
Oedema peripheral
1%
Myocardial infarction
1%
General physical health deterioration
1%
Herpes zoster
1%
Status epilepticus
1%
Gastric haemorrhage
1%
Blood pressure increased
1%
Pulmonary embolism
1%
Coagulopathy
1%
Intestinal infarction
1%
Left ventricular dysfunction
1%
Intestinal ischaemia
1%
Lung infection
1%
Cerebrovascular accident
1%
Intracranial pressure increased
1%
Death
1%
Brain oedema
1%
Subarachnoid haemorrhage
1%
Liver function test increased
1%
Tracheobronchitis
1%
Agitation
1%
Respiratory failure
1%
Hypoxic-ischaemic encephalopathy
1%
Stroke in evolution
1%
Acute kidney injury
1%
Leg amputation
1%
Stridor
1%
Acute respiratory distress syndrome
1%
Diabetic foot
1%
Metabolic alkalosis
1%
Pulmonary congestion
1%
Hepatocellular injury
1%
Bacterial sepsis
1%
Pneumonia bacterial
1%
Lactic acidosis
1%
Lung cancer metastatic
1%
Pneumothorax spontaneous
1%
Peripheral vascular disorder
1%
Gout
1%
Acute myocardial infarction
1%
Hypotension
1%
Pulmonary hypertension
1%
Pulmonary oedema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cefiderocol
Meropenem
Trial Design
1Treatment groups
Experimental Treatment
Group I: CefiderocolExperimental Treatment1 Intervention
Participants will receive four to six doses of Cefiderocol as per current prescribing information based on effluent rate
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cefiderocol
2020
Completed Phase 3
~1800
Find a Location
Who is running the clinical trial?
Hartford HospitalLead Sponsor
135 Previous Clinical Trials
19,070 Total Patients Enrolled
Shionogi Inc.Industry Sponsor
8 Previous Clinical Trials
714 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not pregnant or breastfeeding.I do not have a condition that could lead to death within 48 hours.I am 18 years old or older.I am currently on continuous renal replacement therapy.
Research Study Groups:
This trial has the following groups:- Group 1: Cefiderocol
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger